Potencial terapêutico de formulações no tratamento de feridas cutâneas

Abstract

Healing of skin wounds is a complex process that aims to restore tissue integrity. Currently in the veterinary clinical routine there are several treatments that help in this process stimulating healing. In this sense, medicinal plants already used for the treatment of diseases, are a growing alternative in the veterinary branch for the treatment of cutaneous lesions. However, for the development of a commercial product, it is necessary to prove use of action and safety. The objective of this study was to evaluate the applicability of formulas containing plant extracts in the treatment of cutaneous lesions in ex vivo and in vivo experiments. Initially the extracts were obtained and two different pharmaceutical formulas were made, the first call of LCFT 2001 and the second call of LCFT 2002. In the in vivo studies were determined methodological parameters of temperature, time of exposure and body region for the confection of second-degree thermal lesions. It was evaluated the therapeutic effect of the formulations with the induction of thermal lesions in experimental animals, dividing them into four daily treatment groups: LCFT 2001, LCFT 2002, commercial product with active collagenase (CP) and absence of treatment (CN). At two, five, eight, 14 and 25 days of treatment the lesions were evaluated for clinical parameters, cicatrization and histopathological retraction, and at 25 days for tensiometry. The anti-inflammatory effect was also investigated with the induction of rat ears with 10% chroton oil, and after one hour they received the following treatments: LCFT 2001, LCFT 2002, commercial product containing dexamethasone (CP), physiological solution NaCl 0.9% (CN). After six hours of induction, ear samples were analyzed clinically and histopathologically. In the toxicity study, ocular bulbs from chickens were used, which received 500μL or 0.5g of the proposed treatments: LCFT 2001, LCFT 2002, 10% acetic acid (CP) and physiological solution NaCl 0.9% (CN). After instillation of the products and at 30, 75, 120, 180 and 240 minutes, the eyes were evaluated for fluorescein retention, opacity and corneal edema parameters. It has been found that temperatures between 90 ° and 100 °, by 15 ° or 20 °, in the thoracic region reproduce thermal lesion of second degree. The healing effect of the collagenase-like pharmaceutical formulas was observed, with exacerbation of inflammation removing necrosis and proliferating granulation in the first days of treatment, as well as stimulation of collagen development and reepithelialization at 14 and 25 days of treatment, forming a resistant scar. It was also found that the formulas expressed proinflammatory action reaching a similar effect of dexamethasone. In addition, the formulas did not present significant opacity and corneal edema, classifying them as non-irritating to the eye. Thus, it is concluded that the formulas containing plant extract actives have healing properties, anti-inflammatory properties and are safe for ocularirritation, which made possible the application of a patent registration made in September 2018.